As Hormone Use Increases, Some Doctors Warn Slight Cancer Risk Is Being Overlooked

According to MedPage Today, doctors are warning not to overlook the small increase in breast cancer risk associated with certain hormonal therapies for treating menopause symptoms. The New York Times reported that as hormone use increases, some doctors warn that this slight cancer risk is being overlooked. MedPage Today also mentioned that the FDA removed boxed warnings about breast cancer, cardiovascular disease, and dementia from the labels of three estrogen patches, as reported by The Guardian.

The Seattle Times stated that as menopause hormones gain favor, experts say ‘keep cancer in the conversation’. Bel Marra Health explained that hormone therapy for menopause has undergone changes, and it is essential to understand what these changes mean. Contemporary OB/GYN published a Q&A with Soma Mandal, MD, MSCP, on FDA boxed warning removals for MHT.

Yahoo Health reported that flawed studies linking hormone therapy to breast cancer made doctors reluctant to prescribe it for menopause relief. Oncodaily mentioned that the Onco-Menopause Conference highlighted the importance of menopause care in cancer survivorship, according to Muna Al-Khaifi. MedPage Today also discussed various other topics, including oncology pay cuts, mammograms post-double mastectomy, and new drug applications for cancer treatments.

The Washington Post published an opinion piece stating that a landmark study was flawed, and now the author's mother is losing her memory. The New York Times emphasized the importance of considering the slight cancer risk associated with hormone therapy for menopause.

RealClearHealth reported that HHS is delivering wins for women, but the article did not specifically mention the cancer risk associated with hormone therapy. AFR mentioned that women in their late 30s are demanding HRT, but the article did not provide further information on the cancer risk.

In related news, MedPage Today reported on various cancer-related topics, including a new swab test for endometrial cancer, a trial for cutting-edge blood tests to detect early-stage cancers, and the link between surgery and better survival rates for early-stage non-small cell lung cancers.

The Association for Clinical Oncology stated that oncologists treating Medicare patients will face a roughly 2% pay cut under the 2027 Physician Fee Schedule from CMS. Karyopharm Therapeutics filed for bankruptcy and announced plans to merge with Ayrmid Ltd.

Newly approved pancreatic cancer drug daraxonrasib generated $198 million in sales, according to maker Revolution Medicines. The first patient to receive an mRNA vaccine designed to treat stage II pancreatic cancer is thriving 7 years later, as reported by NPR.

Overall, the sources agree that there is a slight cancer risk associated with hormone therapy for menopause, and it is essential to consider this risk when prescribing or undergoing treatment.

The sources provided various statistics and information on cancer research and treatment, but they did not specify what is scheduled or expected next regarding the cancer risk associated with hormone therapy for menopause.

In conclusion is not allowed, so: The information provided by the sources highlights the importance of considering the slight cancer risk associated with hormone therapy for menopause, and further research and discussion are necessary to fully understand this risk.